News

The study will assess disease activity subsequent to treatment with BI-505 in around 10 patients. Safety, pharmacokinetics and assessment of biomarkers are the secondary objectives of the study.

The commission was awarded for the development of induced pluripotent stem cell (iPSC) lines that are created from tissue donated by the patients with Alpha-1 Antitrypsin Deficiency (Alpha-1).

The new mammalian cGMP CBF will be available as part of a larger development and manufacturing programme, or as a stand-alone service. Fujifilm Diosynth Biotechnologies UK managing director

As part of the CRM deployment, Ferring Italy has also deployed Cegedim’s OneKey, which is the world’s healthcare professional database and help desk. The cloud based Mobile Intelligence

The move marks a major step in setting up a single Trans-Tasman regulatory agency for therapeutic products. New Zealand Health Minister Tony Ryall, in a joint statement, said

The186-gene signature is used to determine the prognosis of patients diagnosed with liver cancer, hepatocellular carcinoma (HCC), or with hepatitis C-related early-stage cirrhosis. During the period of exercising

TC-5619 is developed as a treatment for negative symptoms and cognitive dysfunction in schizophrenia. Targacept president and chief executive officer Dr. Stephen Hill said existing schizophrenia therapies primarily

The trial will enrol 1,400 patients and randomise them with either NT-300, placebo (sugar pill), oseltamivir (Tamiflu) or NT-300 plus oseltamivir. The primary objectives of the study are

OMS721 works by blocking the lectin pathway of the complement system while leaving intact the classical pathway and selectively inhibits MASP-2 representing the acquired immune response to infection.